BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy...
BioCentury | Mar 13, 2020
Emerging Company Profile

Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

Danish newco Twelve Bio is building a CRISPR-Cas12a toolbox comprising a suite of Cas12a variants that are more efficient, precise and safe to use than the wild type Cas12a enzyme for both diagnostic and therapeutic...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
BioCentury | Mar 11, 2020
Politics, Policy & Law

Insulin companies commit to CMS program that caps Medicare out-of-pocket insulin costs

The three major U.S. insulin suppliers, Eli Lilly, Novo Nordisk and Sanofi, said they will participate in a program CMS announced Wednesday that will cap out-of-pocket insulin costs for Medicare beneficiaries. CMS will allow enhanced...
BioCentury | Feb 25, 2020
Product Development

NGM pops on additional Phase II NASH data for aldafermin

Positive histology data helped NGM snap a losing streak for NASH therapies and lifted the biotech’s stock on a day where the sector and broader markets saw mostly red. Shares of NGM Biopharmaceuticals Inc. (NASDAQ:NGM)...
BioCentury | Feb 15, 2020
Product Development

The Phase III trials and pharma sales most likely to be disrupted by COVID-19

The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth. In an analysis of MNC revenues and dependence on trial sites in China,...
BC Extra | Feb 1, 2020
Company News

Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations

Among a series of recommendations issued Friday, EMA’s CHMP backed approval of what would be Alnylam’s second approved RNAi drug in the EU, as well as an oral diabetes therapy that Novo Nordisk is relying...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic  FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with Type II diabetes and heart disease....
Items per page:
1 - 10 of 1704
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy...
BioCentury | Mar 13, 2020
Emerging Company Profile

Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

Danish newco Twelve Bio is building a CRISPR-Cas12a toolbox comprising a suite of Cas12a variants that are more efficient, precise and safe to use than the wild type Cas12a enzyme for both diagnostic and therapeutic...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
BioCentury | Mar 11, 2020
Politics, Policy & Law

Insulin companies commit to CMS program that caps Medicare out-of-pocket insulin costs

The three major U.S. insulin suppliers, Eli Lilly, Novo Nordisk and Sanofi, said they will participate in a program CMS announced Wednesday that will cap out-of-pocket insulin costs for Medicare beneficiaries. CMS will allow enhanced...
BioCentury | Feb 25, 2020
Product Development

NGM pops on additional Phase II NASH data for aldafermin

Positive histology data helped NGM snap a losing streak for NASH therapies and lifted the biotech’s stock on a day where the sector and broader markets saw mostly red. Shares of NGM Biopharmaceuticals Inc. (NASDAQ:NGM)...
BioCentury | Feb 15, 2020
Product Development

The Phase III trials and pharma sales most likely to be disrupted by COVID-19

The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth. In an analysis of MNC revenues and dependence on trial sites in China,...
BC Extra | Feb 1, 2020
Company News

Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations

Among a series of recommendations issued Friday, EMA’s CHMP backed approval of what would be Alnylam’s second approved RNAi drug in the EU, as well as an oral diabetes therapy that Novo Nordisk is relying...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic  FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with Type II diabetes and heart disease....
Items per page:
1 - 10 of 1704